touchONCOLOGY joins Dr Valsamo Anagnostou (Johns Hopkins University School of Medicine, Baltimore, MD, USA ) at WCLC 2021 to discuss her presentation on the circulating tumor DNA biomarker-directed blood test and immune checkpoint inhibitor therapy in people with advanced non-small cell lung cancer.
Clinical Trial Registry Identifiers: CRI-CCTG0002/BR.36, NCT04093167.
Questions
1. What are the major challenges of immune checkpoint inhibitor therapy in people with advanced non-small cell lung cancer? (00:10-01:36)
2. Could you tell us a little about the circulating tumor DNA biomarker-directed blood test, and the clinical evidence supporting its use? (01:36-03:39)
3. What were the aims, design and patient population of your phase II study? (03:39-05:55)
4. What are the primary outcome measures planned for this study? (05:55-06:45)
5. What future studies are planned? (06:45-08:18)
Disclosures: Valsamo Anagnostou receives research funding from Bristol Myers Squibb and AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 WCLC Annual Meeting.
